Celldex Therapeutics (CLDX) Rating Reiterated by WBB Securities
Celldex Therapeutics (NASDAQ:CLDX)‘s stock had its “buy” rating reiterated by analysts at WBB Securities in a report released on Wednesday. They currently have a $10.00 price objective on the biopharmaceutical company’s stock. WBB Securities’ price objective suggests a potential upside of 244.83% from the company’s current price.
A number of other research analysts have also commented on the stock. HC Wainwright restated a “buy” rating on shares of Celldex Therapeutics in a research report on Tuesday, November 7th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $9.00 price objective on shares of Celldex Therapeutics in a report on Tuesday, September 26th. Finally, ValuEngine downgraded shares of Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st. Three equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $7.05.
Celldex Therapeutics (NASDAQ:CLDX) remained flat at $$2.90 on Wednesday. 654,200 shares of the company’s stock traded hands, compared to its average volume of 1,670,226. Celldex Therapeutics has a 52-week low of $2.20 and a 52-week high of $4.07.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. lifted its holdings in shares of Celldex Therapeutics by 7.8% during the 2nd quarter. Vanguard Group Inc. now owns 9,774,858 shares of the biopharmaceutical company’s stock worth $24,143,000 after acquiring an additional 708,095 shares during the last quarter. Meditor Group Ltd lifted its stake in Celldex Therapeutics by 8.8% in the third quarter. Meditor Group Ltd now owns 6,312,700 shares of the biopharmaceutical company’s stock worth $18,054,000 after purchasing an additional 512,700 shares during the last quarter. State Street Corp lifted its stake in Celldex Therapeutics by 4.7% in the first quarter. State Street Corp now owns 4,525,051 shares of the biopharmaceutical company’s stock worth $16,341,000 after purchasing an additional 202,375 shares during the last quarter. Northern Trust Corp lifted its stake in Celldex Therapeutics by 12.2% in the second quarter. Northern Trust Corp now owns 2,020,797 shares of the biopharmaceutical company’s stock worth $4,992,000 after purchasing an additional 219,661 shares during the last quarter. Finally, TSP Capital Management Group LLC lifted its stake in Celldex Therapeutics by 6.8% in the second quarter. TSP Capital Management Group LLC now owns 1,135,748 shares of the biopharmaceutical company’s stock worth $2,805,000 after purchasing an additional 72,500 shares during the last quarter. 52.55% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: “Celldex Therapeutics (CLDX) Rating Reiterated by WBB Securities” was reported by American Banking News and is owned by of American Banking News. If you are reading this story on another publication, it was illegally stolen and reposted in violation of international copyright and trademark law. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/12/06/celldex-therapeutics-cldx-rating-reiterated-by-wbb-securities.html.
About Celldex Therapeutics
Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.
Receive News & Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.